Patients
Latest news and updates related to patients
About Patients coverage
The Patients news hub on Global Investing News tracks 9 recent headlines that matter to investors, policy watchers, and market strategists. Use this page to monitor how Patients developments affect earnings expectations, sector rotation, supply chains, regulation, and cross-asset volatility. Stories are grouped by source type — market data, company announcements, regulatory filings, and expert analysis — so you can scan the signal quickly without wading through duplicate wire copy. When a headline links to a full article, you will find expanded context, key facts, and prediction-market angles where available. Bookmark this hub if you follow Patients across quarters; new items are added as our crawl pipeline ingests fresh sources throughout the trading day.
Explore related topics
Latest Patients headlines
Market Data
(4)A new Medicare program that uses AI for prior authorizations is hurting patients and delaying care
A new Medicare program that uses AI for prior authorizations is hurting patients and delaying care
It’s not just patients who are sick of fighting health insurers. Doctors are frustrated, too.
This MarketWatch headline highlights growing discontent within the healthcare industry, indicating that both patients and medical professionals are increasingly frustrated with health insurance practices. This widespread dissatisfaction could lead to calls for regulatory changes, impact patient care, and potentially affect the financial performance of health insurers if it results in higher administrative costs or reforms that limit their profitability. Investors should monitor legislative developments and insurer responses to these pressures.
‘This is an overlooked catastrophe’: Why do so many hospitals not accept Medicare Advantage for cancer patients?
This MarketWatch headline exposes a critical issue: many hospitals are reportedly not accepting Medicare Advantage (MA) plans for cancer patients, leading to significant care access barriers. This development implies growing friction between healthcare providers and MA plans, potentially impacting patient outcomes and hospital revenues. Investors should monitor evolving reimbursement policies, hospital financial stability, and regulatory responses as this trend could accelerate policy changes affecting both insurers and providers.
Taking the new Wegovy pill every day is really complicated. Will patients stick with it?
Taking the new Wegovy pill every day is really complicated. Will patients stick with it?
Other Sources
(5)Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
Making U.S. biotech more competitive with China's could help rare disease patients, experts say
Experts suggest that increasing the competitiveness of the U.S. biotechnology sector against China's could significantly benefit patients suffering from rare diseases. By fostering innovation and efficiency within the domestic biotech industry, the U.S. could accelerate the development and accessibility of crucial treatments for these underserved patient populations, thereby improving health outcomes and reducing reliance on foreign supply chains.
A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.
A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
Eli Lilly announced positive results for its investigational oral obesity drug, orforglipron, showing it effectively maintained weight loss in patients who transitioned from injectable GLP-1 agonists like Wegovy and Zepbound. This marks a potential breakthrough for patients seeking a more convenient oral alternative for long-term weight management after initial significant loss with injectables.
Eli Lilly’s newest weight-loss drug relieved pain in patients with knee osteoarthritis
Eli Lilly's experimental weight-loss drug, likely Zepbound (tirzepatide), has shown a promising secondary benefit by significantly reducing pain in patients suffering from knee osteoarthritis. This finding suggests a potential double utility for the drug, addressing both obesity and a common chronic pain condition, which could broaden its market and impact on patient health beyond just weight management.
Get alerts for this topic
Subscribe to receive updates about "Patients"